Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 9/20 | 0.61 |
| ▸ | HTR2A | P28223 | 3/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.45 |
| ▸ | HTR1A | P08908 | 6/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15901130 | 0.88 | HTR2C (0.43) | HTR2CHTR2A | |
| SCHEMBL29361990 | 0.83 | HPGD (0.45) | HTR2CHTR2AHTR1A | |
| SCHEMBL2707057 | 0.82 | HTR2C (0.63) | HTR2CHTR2ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22542016 | 0.82 | SLC6A2 (0.63) | HTR2CHTR2ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL23712339 | 0.81 | HTR2C (0.61) | HTR2CHTR2ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6036481 | 0.81 | HTR2C (0.66) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL5669793 | 0.81 | HTR2C (0.61) | HTR2CHTR2ASLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL4891726 | 0.79 | HTR2C (0.67) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| Hydrochloric Acid SCHEMBL5669804 | 0.79 | HTR2C (0.62) | HTR2CHTR2ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6709455 | 0.79 | HTR2C (0.59) | HTR2CHTR2ASLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11261164-B2 | Small molecule agonists of neurotensin receptor 1 | Sanford Burnham Prebys Medical Discovery Institute (US) | 2022-03-01 | — | — | US | disclosed |
| US-20200354324-A1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2020-11-12 | — | — | US | disclosed |
| US-20200354324-A1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2020-11-12 | — | — | US | disclosed |
| US-10584103-B2 | Small molecule agonists of neurotensin receptor 1 | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-03-10 | — | — | US | disclosed |
| US-20190023665-A1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | Sanford Burnham Prebys Medical Discovery Institute | 2019-01-24 | — | — | US | disclosed |
| US-20190023665-A1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | Sanford Burnham Prebys Medical Discovery Institute | 2019-01-24 | — | — | US | disclosed |
| US-10118902-B2 | Small molecule agonists of neurotensin receptor 1 | Sanford Burnham Prebys Medical Discovery Institute (US) | 2018-11-06 | — | — | US | disclosed |
| US-20170240514-A1 | Small Molecule Agonists of Neurotensin Receptor 1 | Sanford Burnham Prebys Medical Discovery Institute | 2017-08-24 | — | — | US | disclosed |
| US-20170240514-A1 | Small Molecule Agonists of Neurotensin Receptor 1 | Sanford Burnham Prebys Medical Discovery Institute | 2017-08-24 | — | — | US | disclosed |
| US-20170240514-A1 | Small Molecule Agonists of Neurotensin Receptor 1 | Sanford Burnham Prebys Medical Discovery Institute | 2017-08-24 | — | — | US | disclosed |
| EP-3160961-A2 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | Sanford-Burnham Medical Research Institute (US) | 2017-05-03 | — | — | EP | disclosed |
| WO-2015200534-A2 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10584103-B2 | Small molecule agonists of neurotensin receptor 1 | NTSR1, NTSR2, VIPR1 | HTR2C 279/4885HTR2A 252/4885SLC6A2 322/4885 |
| US-11261164-B2 | Small molecule agonists of neurotensin receptor 1 | NTSR1, NTSR2, VIPR1 | HTR2C 279/4885HTR2A 252/4885SLC6A2 322/4885 |
| US-20170240514-A1 | Small Molecule Agonists of Neurotensin Receptor 1 | NTSR1, NTSR2, VIPR1 | HTR2C 279/4885HTR2A 252/4885SLC6A2 322/4885 |
| US-10118902-B2 | Small molecule agonists of neurotensin receptor 1 | NTSR1, NTSR2, VIPR1 | HTR2C 279/4885HTR2A 252/4885SLC6A2 322/4885 |
| US-20200354324-A1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | NTSR1, NTSR2, VIPR1 | HTR2C 279/4885HTR2A 252/4885SLC6A2 322/4885 |
| US-20190023665-A1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | NTSR1, NTSR2, VIPR1 | HTR2C 279/4885HTR2A 252/4885SLC6A2 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.